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INTRODUCTION
Copy-number variation is a large source of variation in the 
human genome. Within an individual genome, copy-number 
variants (CNVs) are estimated to result in a 1.2% difference 
in comparison to the reference genome.1 CNVs not only con-
tribute to normal genomic variation but are also an important 
cause of disease. Clinically relevant CNVs can be identified in 
patients with intellectual disability (ID) and other neurode-
velopmental disorders; for example, they have been identified 
in an estimated 10–20% of ID patients.2–5 As a consequence, 
microarray-based CNV profiling has been introduced as a first-
tier diagnostic test for neurodevelopmental disorders in many 
laboratories in the past decade. Although research studies have 
implied an important role for CNVs in several other diseases,6–8 
the diagnostic genetic testing strategy for nonneurodevelop-
mental disorders has focused primarily on the detection of 
small genetic variants such as (point) mutations and inser-
tion-deletions, using, for example, Sanger sequencing. With 
these disorders, microarray-based CNV profiling is not part of 
standard clinical practice. Recently, however, next-generation 
sequencing (NGS) approaches such as whole-exome sequenc-
ing have been implemented for these disorders in an increasing 
number of diagnostic laboratories. Although exome sequenc-
ing is used mostly to study the role of small variants, it is also 
suitable for the detection of larger structural variation such as 
CNVs.
The identification of CNVs in exome data can be performed 
using depth-of-coverage analysis. Several algorithms have been 
developed using a read-depth approach to identify CNVs in 
exome sequencing data.9–12 Owing to the targeted nature of 
exome-capture platforms, the sensitivity of identifying CNVs 
containing three or more exons has been estimated to be 76%, 
with a specificity of 94%.11 Alternative approaches for identify-
ing structural variants in NGS data such as split-read or discor-
dant pairs are less suited for identifying large events in exome 
sequencing data due to the fragmented nature of the data.
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Purpose: Copy-number variation is a common source of genomic 
variation and an important genetic cause of disease. Microarray-
based analysis of copy-number variants (CNVs) has become a first-
tier diagnostic test for patients with neurodevelopmental disorders, 
with a diagnostic yield of 10–20%. However, for most other genetic 
disorders, the role of CNVs is less clear and most diagnostic genetic 
studies are generally limited to the study of single-nucleotide variants 
(SNVs) and other small variants. With the introduction of exome 
and genome sequencing, it is now possible to detect both SNVs and 
CNVs using an exome- or genome-wide approach with a single test.
Methods: We performed exome-based read-depth CNV screening 
on data from 2,603 patients affected by a range of genetic disorders 
for which exome sequencing was performed in a diagnostic setting.
Results: In total, 123 clinically relevant CNVs ranging in size from 
727 bp to 15.3 Mb were detected, which resulted in 51 conclusive 
diagnoses and an overall increase in diagnostic yield of ~2% (ranging 
from 0 to –5.8% per disorder).
Conclusions: This study shows that CNVs play an important role 
in a broad range of genetic disorders and that detection via exome-
based CNV profiling results in an increase in the diagnostic yield 
without additional testing, bringing us closer to single-test genomics.
Genet Med advance online publication 27 October 2016
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In this study, we evaluated the clinical application of exome-
based CNV profiling in a cohort of 2,603 individuals who 
underwent exome sequencing as a diagnostic test. These indi-
viduals were affected by a broad range of diseases that fell 
within 1 of 13 genetic-disorder categories ranging from neuro-
developmental and sensory disorders to congenital abnormali-
ties to hereditary cancers.
MATERIALS AND METHODS
Sample selection
We collected 2,603 samples in 13 genetic-disorder categories: 
neurodevelopmental disorders, blindness, deafness, immu-
nodeficiency, movement disorders, muscle disorders, renal 
disorders, craniofacial anomalies, disorders of sexual develop-
mental, mitochondrial oxidative phosphorylation disorders, and 
metabolic disorders (Figure 1a). The germ line of 73 patients 
with microsatellite stable colorectal cancers was also analyzed. 
Finally, 119 patients with complex phenotypes were included 
(Supplementary Table S1 online). The exome sequencing data 
for all samples were previously analyzed for (potential) patho-
genic small variants (mutations) that were found within a cor-
responding panel of disease genes as previously described.13 In 
addition, the majority of the neurodevelopmental disorders sam-
ples had previously screened negative for CNVs, based mostly 
on Affymetrix 250k microarray data using an average resolution 
of 100 kb for deletions and 150 kb for duplications. CNV analy-
sis was performed for all exome samples. First, it was performed 
for CNVs overlapping genes associated with the genetic-disor-
der category. Second, exome-wide analysis with a resolution of 
200 kb was performed anonymously for all patients.
Exome sequencing
The SureSelect V4 exome kit was used for enrichment of all 
samples. Sequencing was performed on the Solid 5500xl for 
525 samples, with sequence reads mapped using Lifescope ver-
sion 1.3 (Life Technologies, MA). For 2,078 samples, Illumina 
HiSeq2000 sequencing was performed and reads were mapped 
using bwa (version 0.7.7, Illumina, CA). The exome sequencing 
was performed with a minimum median coverage of 80×.
CNV calling
CNV calling was performed using CoNIFER (http://conifer.
sourceforge.net/)11 for two batches based on sequencing tech-
nology. All Illumina samples were processed in one batch (n = 
2,078), and all 5,500 Solid samples were processed in a second 
batch (n = 525). CNVs with an absolute Z-score greater than 
1.7 were considered for analysis. Samples with a total number 
of CNVs exceeding two standard deviations from the mean 
number of CNV segments were presumed to have poor quality 
and excluded from further analysis (n = 121). This equated to 
samples with more than 75 CNV segments sequenced on the 
Solid 5500xl platform and more than 97 CNV segments in sam-
ples from the Illumina HiSeq2000 platform. All deletion events 
were considered disruptive, as were duplications in known fully 
penetrant microdeletion/duplication regions14 and intragenic 
CNV duplications. CNVs that overlapped known regions of 
partial penetrance were considered separately.14
To determine the presence of a potential batch effect, prin-
cipal component analysis was performed on the normalized 
read-depth values (rpkms) of the Illumina samples. In total, the 
2,078 samples were divided into 12 batches and colored accord-
ingly. The first two components were then plotted according 
to the batch in which they were processed (Supplementary 
Figure S1 online).
CNV annotation
CNVs were annotated based on the number of RefSeq exons 
affected, frequency of CNVs within the cohort, and overlap 
with disease gene panels per cohort.15 Furthermore, the overlap 
was calculated with OMIM (Online Mendelian Inheritance in 
Man) disease genes,16 DECIPHER known syndromes (https://
decipher.sanger.ac.uk/),14 and the American College of Medical 
Genetics and Genomics list of 56 medically actionable genes.17
Validation
Clinically relevant CNVs classified as pathogenic were validated 
using multiple validation strategies. Affymetrix CytoScanHD 
(Affymetrix, CA) microarrays were used to validate events 
larger than 200 kb when the target region had sufficient probe 
coverage. For all smaller CNVs, MLPA (MRC-Holland, The 
Netherlands) was used based on the availability of a commer-
cial kit; otherwise, a custom Multiplex Amplicon Quantification 
(MAQ) assay (Multiplicon, Belgium) was performed.18 In addi-
tion, the inheritance was determined for potentially clinically 
relevant CNVs in patients from the neurodevelopmental-disor-
ders cohort. Read counts for the chr17 H2 allele were calculated 
using Samtools (http://www.htslib.org/)19 based on the number 
of reads mapped to chr17_ctg5. PCR validation experiments 
were then performed to confirm the predicted H1/H2 genotype.
RESULTS
Our patient cohort consisted of 2,603 patients who underwent 
exome sequencing to identify the genetic origin of their disease. 
In total, 13 genetic-disorder categories were included, includ-
ing deafness, blindness, metabolic disorders, immunodefi-
ciency, movement disorders, renal disorders, and hereditary 
cancers (Supplementary Table S1 online; Figure 1a). Exome 
CNV analysis of the exome sequencing data was performed 
in two tiers, whereby all known disease genes relevant to the 
patient’s phenotype were investigated. The disease categories 
were used to determine which disease gene panel should be 
applied when performing this first-tier targeted analysis. A sub-
set of 42 patients was analyzed for more than one gene panel 
(Supplementary Table S1 online). In a second tier, exome-wide 
analysis was performed depending on the informed consent 
given. Exome sequencing data were derived from two different 
NGS platforms: the 5500xl SOLiD system (Life Technologies) 
(n = 525) and the HiSeq2000 system (Illumina) (n = 2,078). 
Exome-based CNV profiling by read-depth analysis was per-
formed with the CoNIFER algorithm11 for all 2,603 samples.
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Qualitative analysis of the data set via principal compo-
nent analysis of read depth per exon values (rpkm) showed 
that samples processed for exome sequencing in the same 
time period and the same sequencing platform tend to cluster 
(Supplementary Figure S1 online). Therefore, data normaliza-
tion was performed using the entire cohort of samples as a refer-
ence to cover most sources of variation, as is often also done for 
microarray data.20 Exome-based CNV profiling of our data set 
was also influenced by the genomic architecture of the 17q21.31 
locus (Koolen–de Vries syndrome region (OMIM 610443)). 
This region in the human genome harbors a common 900-kb 
inversion polymorphism that results in two major haplotypes: 
H1 and H2 (inversion). Exome-based CNV analysis revealed 
numerous deletions of this region, which turned out to be false-
positive events. K-means clustering of rpkm values revealed 
three distinct read-depth clusters that were used to distinguish 
carriers of the H1 and H2 microinversion alleles in this 17q21 
region, all with a normal copy number (Supplementary Figure 
S2 online).
Across the complete cohort (n = 2,603), exome-based CNV 
profiling identified an average of six CNVs per patient with a 
mean size of 127 kb (range, 727 bp to 15.3 Mb), affecting, on 
average, three genes (range, 1 to 95 genes) (Supplementary 
Table S2 online).
Diagnostic yield
We first identified rare deletions and intragenic duplication 
events that affected one or more disease genes relevant for the 
patient’s disorder, using the corresponding disease-category 
gene panels as established for diagnostic exome sequenc-
ing interpretation within our department (http://www.
genomediagnosticsnijmegen.nl/services/exome-sequencing-
diagnostics). Intergenic duplications were excluded in this 
study because of the complexities in determining the con-
sequences at both the functional and genomic architectural 
levels. CNVs were considered clinically relevant if they con-
tained one or more disease genes for which the phenotype 
described in the literature corresponded with the patient’s phe-
notype. For recessive disease genes, the corresponding exome 
sequencing data were analyzed for the presence of a second 
pathogenic variant in the gene, such as a point mutation,21 
indel,22 or mobile element insertion23 that could contribute 
to a compound heterozygous event. We identified clinically 
relevant CNVs in 123 patients from the total cohort of 2,603 
patients (Figure 1b). For 51 patients, a conclusive diagnosis 
could be made based on a validated pathogenic CNV in which 
the genetic diagnosis and inheritance pattern matched the 
clinical phenotype (Table 1). For another 45 patients, a CNV 
affected a recessive gene matching the clinical phenotype but 
no second mutation on the second allele was identified in the 
exome sequencing data that could result in a possible diagno-
sis.24 In addition, for 12 patients, a CNV was identified that 
affected a known susceptibility locus (a known CNV region 
with reduced penetrance) for the disorder under investigation, 
which also resulted in a possible diagnosis (Table 2).
Across the complete cohort, the highest diagnostic yields were 
obtained for deaf patients (5.8%, 13 of 223 patients), patients 
with a complex phenotype (5.5%, 10 of 183), and patients with 
a renal disorder (3.6%, 2 of 56 patients). The pathogenic CNVs 
ranged in size from 727 bp to 15.3 Mb, with a median size of 
420 kb and a standard deviation of 1.9 Mb (mean size, 1.1 Mb). 
No clinically relevant CNVs were identified in disorders of 
sexual development (31 patients), craniofacial anomalies (24 
patients), metabolic disorders (38 patients), and hereditary 
cancers (74 patients). The large difference in the diagnostic 
yield between the various disease categories may be explained 
by different mutational mechanisms causing these diseases and 
by the difference in the number of known disease genes per 
disorder. However, the relatively small sample size per disease 
group is likely to have also impacted these variable diagnostic 
yields (Table 1).
Of the 2,603 patients, a subset of 1,215 had a neurodevelop-
mental disorder (47% of the total cohort). Within this group, 
exome-based CNV analysis identified 16 events that were con-
firmed as de novo or resulted in loss of function of an auto-
somal-dominant disease gene linked to the clinical phenotype. 
This translates in a diagnostic yield of 1.3% in this disease cat-
egory (Figure 2a; Table 1). This percentage is relatively low 
compared with the yield of >10% reported for genomic micro-
arrays.2–5 This can easily be explained by the fact that the vast 
majority of 1,215 individuals with a neurodevelopmental disor-
der had previously screened negative for CNV microarray anal-
ysis, resulting in a depletion of pathogenic CNVs in this patient 
group. Clinically relevant CNVs were observed only in patients 
who had previously been screened on a (low-resolution) micro-
array platform or in patients who did not receive microarray-
based CNV profiling. Some of these clinically relevant CNVs 
affected known microdeletion and/or duplication syndrome 
regions (https://decipher.sanger.ac.uk/disorders#syndromes/
overview), such as the 22q11 VCF/DiGeorge region (1 deletion, 
3 duplications) (Figure 2a) as well as deletions encompassing 
genes previously linked to intellectual disability (ALG1, MSX2, 
ANKRD11, GATAD2B). Notably, three events larger than 4 Mb 
were identified (an 18p tetrasomy, a 7.5-Mb deletion of chro-
mosome 10 (chr10:127.5–135.0 Mb), and an 8.4-Mb deletion of 
chromosome 3 (chr3:182.7–191.0Mb)).
Inheritance models of pathogenic CNVs
In 51 cases, a conclusive molecular diagnosis could be made 
based on the detection of CNVs in the exome sequenc-
ing data. These cases encompassed 32 CNVs occurring in a 
heterozygous state affecting a dominant disease gene and 19 
pathogenic CNVs in a recessive disease gene occurring either 
homozygously or in a compound heterozygous state (in com-
bination with a second pathogenic mutation of non-CNV 
origin). The cases included heterozygous deletions affecting 
dominant disease genes, such as SCN1A, causing autosomal-
dominant Dravet syndrome (OMIM 607208) in two neuro-
developmental patients with epilepsy and a 804-kb deletion 
of the PAX2 gene causing focal segmental glomerulosclerosis 
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type 7 in a patient with a renal disorder (Figure 2b). Likewise, 
homozygous deletions in recessive conditions were detected, 
such as a homozygous deletion of exon 45–47 in the USH2A 
gene leading to Usher syndrome in a blind patient and a homo-
zygous deletion of the NPHP1 gene in a patient with neph-
ronophthisis (OMIM 256100). Exome-based CNV analysis 
also enabled us to identify compound heterozygous events by 
combining CNV and SNV events. This resulted in detection of 
a heterozygous known pathogenic point mutation in exon 9 of 
the USH2A gene (NM_206933.2:c.1606T>C (p.(Cys536Arg)) 
and a deletion removing exons 25–28 of USH2A on the other 
allele in a patient with a visual disorder. Similarly, a deletion 
of the first 6 exons of PANK2 was observed in combination 
with a hemizygous frameshift mutation in exon 6 (c.1317del 
p.Arg440fs (NM_153638.2)) on the other allele in another 
young patient referred for visual disturbances (Figure 2c).
Table 1 Number of patients per indication with a clinically relevant CNV that has been identified
Number of 
patients
CNVs overlapping Diagnostic yield
Autosomal-
dominant genes
Autosomal-recessive 
genes with second hit nr CNVs
% of 
Cohort
Craniofacial anomalies 31 0 0 0 0.0%
Disorders of sexual development 38 0 0 0 0.0%
Immunodeficiency 24 0 0 0 0.0%
Metabolic disorders 34 0 0 0 0.0%
Hereditary cancera 74 0 0 0 0.0%
Renal disorders 56 1 1 2 3.6%
Complex phenotypesb 183 9 1 10 5.5
Mitochondrial disorders 142 0 1 1 0.7%
Muscle disorders 171 1 0 1 0.6%
Deafness 223 0 13 13 5.8
Movement disorders 217 2 0 2 0.9%
Blindness 237 3 3 5 2.1%
Neurodevelopmental disorders 1,215 16 0 16 1.3%
Totalc 2,645 32 19 51 2.0%
CNV, copy-number variant.
aMicrosatellite stable colorectal cancer. bPatients with complex phenotypes for whom a gene panel with all known OMIM (Online Mendelian Inheritance in Man) disease 
genes was used for analysis. cForty-two patients were analyzed for multiple disease gene panels.
Table 2 Number of patients per indication with a CNV identified in a recessive disease gene or overlapping a region 
with partial penetrance
Number of 
patients
CNVs overlapping Candidate yield CNVs overlapping 
regions with partial 
penetrance
Partial 
penetrance yield
Autosomal-recessive 
genes % of Cohort % of Cohort
Craniofacial anomalies 31 0 0.0% 0 0%
Disorders of sexual development 38 0 0.0% 0 0%
Immunodeficiency 24 1 4.2% 0 0%
Metabolic disorders 34 0 2.9% 0 0%
Hereditary cancera 74 1 1.4% 1 1.4%
Renal disorders 56 2 3.6% 1 1.8%
Complex phenotypesb 183 6 3.8% 2 1.1%
Mitochondrial disorders 142 2 1.4% 1 0.7%
Muscle disorders 171 4 2.9% 5 2.9%
Deafness 223 5 3.6% 0 0%
Movement disorders 217 2 1.4% 1 0.5%
Blindness 237 2 1.3% 2 0.8%
Neurodevelopmental disorders 1,215 20 1.6% 12 1.0%
Totalc 2,645 45 2.5% 25 1%
CNV, copy-number variant.
aMicrosatellite stable colorectal cancer. bPatients with complex phenotypes for whom a gene panel with all known OMIM (Online Mendelian Inheritance in Man) disease 
genes was used for analysis. cForty-two patients were analyzed for multiple disease gene panels.
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Recurrent CNVs
A genetic cause for deafness could be established in 13 patients. 
Remarkably, six of these patients carried an identical 150-kb 
homozygous deletion encompassing six genes, including STRC, 
a known recessive deafness gene (OMIM 603720). This dele-
tion was also observed in four patients who carried a hemizy-
gous missense mutation in the same gene on the other allele. 
The recurrent nature of this deletion, which we identified a total 
of 41 times in a heterozygous state (minor allele frequency 2%), 
is highly suggestive of a founder effect in the Dutch popula-
tion (Figure 2d) and confirms the significance of this locus in 
the molecular diagnosis of this form of recessive deafness.25 
Additionally, two recurrent CNV loci affecting recessive genes 
OTOA and NPHP1 were identified at a lower frequency.
Clinically relevant CNVs outside gene panels
In addition to analyzing the exome sequencing data for clini-
cally relevant CNVs that affected known disease genes, CNV 
analysis was expanded to an exome-wide CNV analysis for rare 
events larger than 200 kb. This analysis was expected to result in 
the identification of additional pathogenic CNVs that could be 
related to the clinical phenotype of the patient. In five patients 
with a neurodevelopmental disorder, a CNV was observed 
that affected a known microdeletion and/or microduplication 
syndrome region that did not encompass a known intellectual 
disability gene and therefore was not identified in the first-tier 
CNV analysis. In addition, the availability of exome sequenc-
ing data from patients as well as unaffected parents allowed 
the detection of de novo CNVs that also did not overlap a 
known ID gene but resulted in a likely positive diagnosis. Three 
patients in the remainder of the cohort received a conclusive 
diagnosis through exome-wide CNV analysis. This included 
a 1.6-Mb homozygous deletion of HINT1 and LYRM7 in a 
patient with suspected mitochondrial disease, a 377-kb dele-
tion affecting ATL3 in a patient with a movement disorder, and 
an Xp11.22 duplication (Xp11.22 microduplication syndrome 
OMIM 300705) in a male patient with a muscle disorder. These 
results indicate that, subject to proper counseling and patient’s 
informed consent, CNV analysis preferably should not be 
limited to the known disease genes and should be expanded 
to include the entire genome, as is also done using microar-
ray technology. Notably, as with all genome-wide tests, using 
a genome-wide CNV approach has the potential to uncover 
unsolicited findings, i.e., CNVs that are not directly related to 
clinical questions but are of medical importance to the patient. 
To estimate the incidence of such unsolicited findings during 
exome-based CNV analysis across the samples included in this 
study, we anonymized the genome-wide CNV data set to deter-
mine the number of CNV events that overlap with genes from 
the ACMG secondary-findings gene list.26,27 This analysis iden-
tified four patients with an unsolicited finding (0.15% of the 
patient cohort) affecting the PMS2, VHL, MYH7, and KCNH2 
genes. Heterozygous loss of function mutations in PMS2 have 
been found to contribute to hereditary nonpolyposis colorec-
tal cancer 4 (614337).28 Similarly, heterozygous mutations have 
also been described in VHL for Von Hippel–Lindau syndrome 
(193300). Heterozygous mutations in KCNH2 have been attrib-
uted to both short (609620) and long (613688) QT syndrome, 
Figure 1  Detection of clinically relevant CNVs in a cohort of broad genetic disorders. (a) The cohort screened for large copy-number variants (CNVs) 
consisting of 2,603 patients spanning 13 heterogeneous disorders, including neurodevelopmental disorders, deafness, blindness, renal disorders, metabolic 
disease, immunodeficiency, muscle disorders, craniofacial anomalies, sex dysmorphy, movement disorders, and hereditary cancers. (b) The number of patients 
for whom a conclusive diagnosis could be made based on a pathogenic CNV and the number of candidate CNVs identified per cohort.
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which can result in sudden cardiac death.26,27 Furthermore, 
MYH7 (160760) mutations can, for example, result in myosin 
storage myopathy, resulting in muscle weakness and atrophy.29
In addition to this ACMG list of genes, we screened for the 
incidence of CNV findings that corresponded to the known 
microdeletion and microduplication susceptibility locus (https://
decipher.sanger.ac.uk/disorders#syndromes/overview), which 
has been reported to have partial penetrance. CNVs affecting 
these susceptibility regions have low penetrance and predispose 
to neurocognitive disorders, but they are also found at low fre-
quency in unaffected individuals.17 Anonymized genome-wide 
CNV analysis in our cohort revealed 25 patients who were 
found to harbor such a CNV with partial penetrance, includ-
ing the 1q21, 16p13.11, and 16p11.2-p12.2 susceptibility loci30,31 
(Supplementary Table S2 online). Notably, only 12 of these 25 
patients were referred for exome sequencing because of a neu-
rodevelopmental disorder, indicating that the other 13 patients 
may be nonpenetrant carriers of these susceptibility loci. Caution 
should be taken because other genes not linked to intellectual 
disability or neurodevelopmental disorders are also known to 
reside within these genomic loci, such as the ABCC6 gene in the 
16p13.11 recurrent microdeletion region, which causes autoso-
mal-recessive pseudoxanthoma elasticum (264800).
DISCUSSION
In this study, we performed exome-wide CNV screening 
based on read-depth analysis of exome sequencing data in a 
large cohort of patients with a broad range of phenotypes. The 
aim was to assess the increase in diagnostic yield that can be 
achieved through exome CNV analysis. It has previously been 
demonstrated that exome-based CNV analysis is a robust 
approach to identifying genomic CNVs, although the specific-
ity is highly dependent on the CNV detection algorithms used 
and estimations of the false-negative and false positive rates 
vary greatly.9–12,32 Read-depth CNV analysis resulted in an over-
all increase in diagnostic yield of 2% in our cohort, representing 
a broad spectrum of genetic disorders. This is in line with the 
diagnostic yield obtained with high-resolution exon microar-
rays in similar cohorts.32
The majority of the 2,603 patients in the cohort analyzed in 
this study were not affected by a neurodevelopmental disorder. 
For most of these diseases, gene mutation analysis by traditional 
Sanger sequencing has been the main diagnostic strategy for 
identifying pathogenic genomic variants. CNV analysis has been 
largely neglected in these disorders, possibly because of limited 
knowledge of their clinical impact. In this study, we identified 
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clinically relevant CNVs that previously would not have been 
discovered via targeted disease gene sequencing. These results 
demonstrate that large CNVs not only are an important cause of 
neurodevelopmental disorders but also evidently play an impor-
tant role in many other genetic diseases. Of note, we identified 
25 patients with known microdeletion and/or microduplica-
tion regions of partial penetrance.14 Twelve of these patients 
were affected by a neurodevelopmental disorder; the remaining 
13 were not. This may be due in part to the partial penetrance of 
these regions. However, due to the elevated rate of CNVs affect-
ing these loci, it could suggest that the phenotypic spectrum of 
these syndromes is broader than initially suspected.33
The quality of CNV detection from exome sequencing data 
is affected by several technical factors, including the existence 
of a batch effect (Supplementary Figure S1 online) as well as 
the underlying genomic architecture of regions and how this is 
represented in the reference genome. The latter was highlighted 
in our study owing to the co-occurrence of alternative H1/H2 
haplotypes for the known 17q21 microdeletion syndrome.34 The 
existence of alternative alleles and their inclusion in the reference 
genome continue to evolve35 and fundamentally impact NGS 
data analysis when the sequence reads are mapped. In addition 
to the alternative ch17_ctg5, the human reference hg19 repre-
sents the HLA loci with six alternative contigs known to contain 
Figure 2 Examples of the inheritance patterns of pathogenic copy-number variants. (a) A deletion of 22q11.21 is identified in a patient with 
neurodevelopmental delay. (b) A heterozygous 800-kb deletion encompassing a dominant gene (PAX2) explains the phenotype of a patient with a renal 
disorder. (c) A compound heterozygous event including a deletion of the first six exons of PANK2 (depicted in the lower left panel) in combination with a 
hemizygous frameshift mutation. c.1317del p.Arg440fs (NM_153638.2) reads with hemizygous mutation in exon 4 (depicted in lower right panel) in a patient 
with visual disturbances. (d) A homozygous deletion encompassing STRC results in a recessive disease pattern, explaining the deafness phenotype.
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several disease genes relevant for severe combined immunodefi-
ciency disorders. Hence, the accurate identification of both SNV 
and CNVs is important in these regions of known complexity. 
More recently, the GRCh38 reference genome includes 261 of 
these “alternative loci scaffolds” that represent 178 human chro-
mosomal regions up to 1 Mb in size that exhibit sufficient vari-
ability to prevent adequate representation by the single primary 
sequence.35 Although it is unlikely that all 178 of these loci will 
result in effects as strong as those demonstrated by the 17q21 
region, it is important to consider the implications that these 
alternative loci will have for CNV detection.
In this study, we focused on the detection of large, clinically 
relevant CNVs from exome data via a read-depth strategy. This 
is one of several approaches for detecting structural variation 
from NGS data.36 The detection of CNVs is also possible using 
discordant read pairs and a split-read strategy. However, algo-
rithms relying solely on discordant read pairs suffer from low 
sensitivity due to the skewed insert size distribution as a result 
of shearing DNA fragments in exome sequencing procedures. 
Although methods using a split-read strategy have the prom-
ise of additionally detecting long indel and small deletions, 
particularly in the size range of 20 to 200 bp,22,37 it is currently 
unknown what the impact of capture biases will be on the abil-
ity to sequence exon targets carrying structural variants in this 
size range. Given the high frequency of variants in this small 
size range, it is likely that split-read methods will be able to 
detect additional pathogenic variants.38
Although it has previously been shown that whole-genome 
sequencing and high-resolution microarray analysis are more 
sensitive than exome sequencing for the detection of subtle 
CNVs,6,39,40 the sensitivity when using exome sequencing data for 
the detection of clinically relevant CNVs containing three exons 
is very high (96%).9 With this study, we demonstrate the clinical 
applicability of exome-based CNV screening in genetic testing. 
Incorporation of CNV analysis in exome sequencing data-anal-
ysis pipelines, which until now have generally focused on SNV 
analysis, increases the diagnostic yield of exome sequencing by 
up to 6% (an average of 2%). Of importance, this increase in 
diagnostic yield is obtained without any additional direct labora-
tory costs. However, such a combined SNV and CNV analysis of 
exome data requires additional optimization of the exome data-
analysis pipelines and subsequent interpretation, validation, and 
reporting stages. Nonetheless, combining SNV and CNV detec-
tion increases the suitability of exome sequencing as a first-tier 
diagnostic test for many, if not most, genetic disorders.
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